

Neuland Laboratories Limited
Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113
Road No. 2, Banjara Hills
Hyderabad, 500 034, Telangana,
India.

Tel: 040 3021 1600 / 23551081
Fax: 040 3021 1602
Email: neuland@neulandlabs.com
www.neulandlabs.com

NEULAND LABORATORIES LIMITED

Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113, Road No. 2, Banjara Hills, Hyderabad - 500034

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2014

PART - I

Amount in ₹ Lacs

Sl. No.	Particulars	Quarter Ended 30.09.2014 (Unaudited)	Quarter Ended 30.06.2014 (Unaudited)	Quarter Ended 30.09.2013 (Unaudited)	Half Year Ended 30.09.2014 (Unaudited)	Half Year Ended 30.09.2013 (Unaudited)	Year Ended 31.03.2014 (Audited)
1	Income from Operations						
	(a) Net Sales / Income from Operations	11,967.51	9,984.79	10,212.48	21,952.30	21,875.90	45,385.01
	(b) Other Operating Income	163.72	282.66	215.98	446.38	684.40	1,184.32
	Total Income from Operations (Net)	12,131.23	10,267.45	10,428.46	22,398.68	22,560.30	46,569.33
2	Expenses						
	(a) Consumption of Raw Materials	6,928.51	6,368.23	5,821.10	13,296.74	12,174.03	24,644.22
	(b) Changes in inventories of finished goods and work in process	(102.59)	(922.35)	(417.84)	(1,024.94)	47.79	12.80
	(c) Employee Benefit Expense	1,227.59	1,054.44	891.56	2,282.03	1,855.08	3,625.51
	(d) Depreciation	389.90	389.90	371.06	779.80	736.24	1,493.86
	(e) Manufacturing Expenses	1,600.09	1,241.51	1,165.86	2,841.60	2,159.47	4,842.24
	(f) Other Expenses	938.76	1,165.17	1,580.47	2,103.93	2,948.77	6,506.06
	Total Expenses	10,982.26	9,296.90	9,412.21	20,279.16	19,921.38	41,124.69
3	Profit from Operations before Other Income, Finance Costs and Exceptional Items (1-2)	1,148.97	970.55	1,016.25	2,119.52	2,638.92	5,444.64
4	Other Income	231.70	73.44	81.30	305.14	153.38	341.48
5	Profit from Ordinary Activities before Finance Costs and Exceptional Items (3+4)	1,380.67	1,043.99	1,097.55	2,424.66	2,792.30	5,786.12
6	Finance Costs	629.89	567.82	630.69	1,197.71	1,220.74	2,363.76
7	Profit from Ordinary Activities after Finance Costs but before Exceptional Items (5-6)	750.78	476.17	466.86	1,226.95	1,571.56	3,422.36
8	Exceptional Items	-	-	-	-	-	-
9	Profit from Ordinary Activities before Tax (7-8)	750.78	476.17	466.86	1,226.95	1,571.56	3,422.36
10	Tax Expense						
	(a) Current tax	178.60	103.90	107.70	282.50	318.20	716.70
	(b) Deferred Tax	164.65	173.83	122.79	338.48	446.39	755.61
	(c) MAT Credit entitlement	(107.21)	(103.90)	(107.70)	(211.11)	(318.20)	(716.70)
11	Net Profit from Ordinary Activities after Tax (9-10)	514.74	302.34	344.07	817.08	1,125.17	2,666.75
12	Extraordinary Items	-	-	-	-	-	-
13	Net Profit for the period (11-12)	514.74	302.34	344.07	817.08	1,125.17	2,666.75
14	Paid-up Equity Share Capital (Face Value ₹10 per share)	772.86	772.63	771.56	772.86	771.56	772.63
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						11,392.57
16	Earnings per Share (EPS) (in ₹)						
	(a) Basic	6.72	3.95	4.50	10.67	14.72	34.87
	(b) Diluted	6.72	3.95	4.50	10.67	14.71	34.86



PART - II

Sl. No.	Particulars	Quarter Ended 30.09.2014 (Unaudited)	Quarter Ended 30.06.2014 (Unaudited)	Quarter Ended 30.09.2013 (Unaudited)	Half Year Ended 30.09.2014 (Unaudited)	Half Year Ended 30.09.2013 (Unaudited)	Year Ended 31.03.2014 (Audited)
A	PARTICULARS OF SHARE HOLDING						
1	Public Shareholding						
	(a) Number of Shares	38,25,199	38,22,899	38,17,199	38,25,199	38,17,199	38,22,899
	(b) Percentage of Shareholding	49.95%	49.94%	49.93%	49.95%	49.93%	49.94%
2	Promoters and Promoter Group Shareholding						
	(a) Pledged / Encumbered						
	-Number of Shares	2,00,000	2,00,000	2,00,000	2,00,000	2,00,000	2,00,000
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	5.22%	5.22%	5.22%	5.22%	5.22%	5.22%
	-Percentage of Shares (as a % of the total share capital of the Company)	2.61%	2.61%	2.62%	2.61%	2.62%	2.61%
	(b) Non-encumbered						
	-Number of Shares	36,32,779	36,32,779	36,27,779	36,32,779	36,27,779	36,32,779
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	94.78%	94.78%	94.78%	94.78%	94.78%	94.78%
	-Percentage of Shares (as a % of the total share capital of the Company)	47.44%	47.45%	47.45%	47.44%	47.45%	47.45%

B INVESTOR COMPLIANTS

Particulars	Quarter Ended 30.09.2014
Pending at the beginning of the quarter	0
Received during the quarter	7
Disposed off during the quarter	7
Remaining unresolved at the end of the quarter	0

NOTES:

- The above unaudited financial results have been reviewed by the Audit Committee at their meeting held on October 28, 2014, and approved and taken on record at the Board of Directors meeting held on October 29, 2014.
- EPS for the quarters is not annualised.
- The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard - AS 17 "Segment Reporting".
- The Company, vide its Letter of Offer dated September 22, 2014, offered 12,25,276 Equity Shares of Face Value of ₹10 each at a price of ₹204 per Equity Share (including Share Premium of ₹194 per Equity Share) for an amount aggregating to ₹2499.56 lacs to the existing Equity Shareholders of the Company on rights basis in the ratio of 4 fully-paid Equity Shares for every 25 fully-paid Equity Shares held by the Equity Shareholders on the record date i.e. August 14, 2014. The issue opened on September 29, 2014 and closed on October 16, 2014. On October 29, 2014 the Company has allotted 12,22,472 Equity Shares, balance Equity Shares being kept in abeyance. The Equity Shares issued vide the said Rights Issue have not been considered for computing Earnings Per Share.



5 The statement of assets and liabilities is as follows:

Amount in ₹ Lacs

Sl No	Particulars	As on 30.09.2014 (Unaudited)	As on 31.03.2014 (Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' Funds		
	(a) Share Capital	772.86	772.63
	(b) Reserves and Surplus	12,207.39	11,487.19
		12,980.25	12,259.82
2	Share Application Money Pending Allotment	5.83	-
3	Non-current Liabilities		
	(a) Long-term Borrowings	4,913.10	3,387.00
	(b) Deferred Tax Liability (Net)	1,364.83	1,026.35
	(c) Other Long-term Liabilities	293.00	293.00
	(d) Long-term Provisions	528.04	513.88
		7,098.97	5,220.23
4	Current Liabilities		
	(a) Short-term Borrowings	14,770.47	14,408.48
	(b) Trade Payables	10,730.25	9,336.80
	(c) Other Current Liabilities	4,625.39	6,167.73
	(d) Short-term Provisions	1,556.17	1,537.11
		31,682.28	31,450.12
	TOTAL	51,767.33	48,930.17
B	ASSETS		
1	Non-current Assets		
	(a) Fixed Assets	16,065.51	16,541.51
	(b) Non-current Investments	764.41	764.41
	(c) Long-term Loans and Advances	2,217.79	2,137.88
	(d) Other Non-current Assets	776.97	745.71
		19,824.68	20,189.51
2	Current Assets		
	(a) Inventories	10,806.56	9,341.74
	(b) Trade Receivables	12,626.76	11,859.20
	(c) Cash and Bank Balances	104.37	28.86
	(d) Short-term Loans and Advances	5,434.98	5,387.00
	(e) Other Current Assets	2,969.98	2,123.86
		31,942.65	28,740.66
	TOTAL	51,767.33	48,930.17

6 In accordance with the requirements to Schedule II of the Companies Act, 2013, the Company has re-assessed the useful lives and residual value of the fixed assets and:

- An amount of ₹98.84 lacs has been adjusted to the opening balance of Reserves & Surplus in respect of those assets where the useful life exhausted as at April 1, 2014
- The profit for the quarter and half year has decreased by ₹11.99 lacs and ₹23.98 lacs on account higher depreciation due to application of Schedule II.

7 Previous quarter / year numbers have been regrouped wherever necessary.

By Order of the Board
For Neuland Laboratories Limited



Dr. D.R. Rao
Chairman & Managing Director

Place: Hyderabad
Date: October 29, 2014